The Food and Drug Administration (FDA) has issued a Refuse to File letter for accelerated approval of Roche's trastuzumab-DM1 (T-DM1) Biologics License Application, which was submitted in July 2010. Roche had requested accelerated approval for T-DM1 based on the results of a single-arm Phase II...